162 related articles for article (PubMed ID: 31162255)
1. Radionuclide Therapy With 177Lu-PSMA in a Case of Metastatic Adenoid Cystic Carcinoma of the Parotid.
Has Simsek D; Kuyumcu S; Agaoglu FY; Unal SN
Clin Nucl Med; 2019 Sep; 44(9):764-766. PubMed ID: 31162255
[TBL] [Abstract][Full Text] [Related]
2. Early Prostate-Specific Antigen Changes and Clinical Outcome After
Gafita A; Heck MM; Rauscher I; Tauber R; Cala L; Franz C; D'Alessandria C; Retz M; Weber WA; Eiber M
J Nucl Med; 2020 Oct; 61(10):1476-1483. PubMed ID: 32111687
[TBL] [Abstract][Full Text] [Related]
3. Systemic Radioligand Therapy with (177)Lu Labeled Prostate Specific Membrane Antigen Ligand for Imaging and Therapy in Patients with Metastatic Castration Resistant Prostate Cancer.
Heck MM; Retz M; D'Alessandria C; Rauscher I; Scheidhauer K; Maurer T; Storz E; Janssen F; Schottelius M; Wester HJ; Gschwend JE; Schwaiger M; Tauber R; Eiber M
J Urol; 2016 Aug; 196(2):382-91. PubMed ID: 26964917
[TBL] [Abstract][Full Text] [Related]
4. Iris metastasis from adenoid cystic carcinoma of parotid gland.
Montero J; Shields CL; Bianciotto C; Shields JA; Ehya H
Cornea; 2011 Mar; 30(3):351-3. PubMed ID: 21045673
[TBL] [Abstract][Full Text] [Related]
5. 68Ga- and 177Lu-Labeled PSMA I&T: Optimization of a PSMA-Targeted Theranostic Concept and First Proof-of-Concept Human Studies.
Weineisen M; Schottelius M; Simecek J; Baum RP; Yildiz A; Beykan S; Kulkarni HR; Lassmann M; Klette I; Eiber M; Schwaiger M; Wester HJ
J Nucl Med; 2015 Aug; 56(8):1169-76. PubMed ID: 26089548
[TBL] [Abstract][Full Text] [Related]
6. Septal, widely infiltrative and clinically occult adenoid cystic carcinoma of the parotid gland.
Coup A; Williamson JM; Curley JW
J Laryngol Otol; 1997 May; 111(5):491-2. PubMed ID: 9205619
[TBL] [Abstract][Full Text] [Related]
7. Third-line treatment and
von Eyben FE; Roviello G; Kiljunen T; Uprimny C; Virgolini I; Kairemo K; Joensuu T
Eur J Nucl Med Mol Imaging; 2018 Mar; 45(3):496-508. PubMed ID: 29247284
[TBL] [Abstract][Full Text] [Related]
8. Adenoid cystic carcinoma of the parotid metastasizing to liver: case report.
Harish K; Mangala Gouri SR
BMC Cancer; 2004 Jul; 4():41. PubMed ID: 15285782
[TBL] [Abstract][Full Text] [Related]
9. Predictive Factors of Response and Overall Survival in Patients with Castration-Resistant Metastatic Prostate Cancer Undergoing
Ahmadzadehfar H; Essler M
J Nucl Med; 2018 Jul; 59(7):1033-1034. PubMed ID: 29653975
[No Abstract] [Full Text] [Related]
10. PSMA radioligand therapy in prostate cancer: overview, latest advances and remaining challenges.
Sachpekidis C; Alberts I; Rominger A; Afshar-Oromieh A
Immunotherapy; 2019 Oct; 11(15):1267-1271. PubMed ID: 31496329
[No Abstract] [Full Text] [Related]
11. EANM procedure guidelines for radionuclide therapy with
Kratochwil C; Fendler WP; Eiber M; Baum R; Bozkurt MF; Czernin J; Delgado Bolton RC; Ezziddin S; Forrer F; Hicks RJ; Hope TA; Kabasakal L; Konijnenberg M; Kopka K; Lassmann M; Mottaghy FM; Oyen W; Rahbar K; Schöder H; Virgolini I; Wester HJ; Bodei L; Fanti S; Haberkorn U; Herrmann K
Eur J Nucl Med Mol Imaging; 2019 Nov; 46(12):2536-2544. PubMed ID: 31440799
[TBL] [Abstract][Full Text] [Related]
12. Prospects of medium specific activity (177) Lu in targeted therapy of prostate cancer using (177) Lu-labeled PSMA inhibitor.
Chakraborty S; Chakravarty R; Shetty P; Vimalnath KV; Sen IB; Dash A
J Labelled Comp Radiopharm; 2016 Jul; 59(9):364-71. PubMed ID: 27264278
[TBL] [Abstract][Full Text] [Related]
13. Cutaneous metastasis from adenoid cystic carcinoma of the parotid gland.
Chang CH; Liao YL; Hong HS
Dermatol Surg; 2003 Jul; 29(7):775-9. PubMed ID: 12828706
[TBL] [Abstract][Full Text] [Related]
14.
Fendler WP; Rahbar K; Herrmann K; Kratochwil C; Eiber M
J Nucl Med; 2017 Aug; 58(8):1196-1200. PubMed ID: 28663195
[No Abstract] [Full Text] [Related]
15. Prostate-specific membrane antigen (PSMA) expression in adenoid cystic carcinoma of the head and neck.
Klein Nulent TJW; Valstar MH; Smit LA; Smeele LE; Zuithoff NPA; de Keizer B; de Bree R; van Es RJJ; Willems SM
BMC Cancer; 2020 Jun; 20(1):519. PubMed ID: 32503460
[TBL] [Abstract][Full Text] [Related]
16. The Effect of Total Tumor Volume on the Biologically Effective Dose to Tumor and Kidneys for
Begum NJ; Thieme A; Eberhardt N; Tauber R; D'Alessandria C; Beer AJ; Glatting G; Eiber M; Kletting P
J Nucl Med; 2018 Jun; 59(6):929-933. PubMed ID: 29419479
[TBL] [Abstract][Full Text] [Related]
17. Investigating the Effect of Ligand Amount and Injected Therapeutic Activity: A Simulation Study for 177Lu-Labeled PSMA-Targeting Peptides.
Kletting P; Schuchardt C; Kulkarni HR; Shahinfar M; Singh A; Glatting G; Baum RP; Beer AJ
PLoS One; 2016; 11(9):e0162303. PubMed ID: 27611841
[TBL] [Abstract][Full Text] [Related]
18. Prostate-specific membrane antigen theranostics: therapy with lutetium-177.
Ferdinandus J; Violet J; Sandhu S; Hofman MS
Curr Opin Urol; 2018 Mar; 28(2):197-204. PubMed ID: 29278583
[TBL] [Abstract][Full Text] [Related]
19. Post-therapeutic dosimetry of 177Lu-DKFZ-PSMA-617 in the treatment of patients with metastatic castration-resistant prostate cancer.
Yadav MP; Ballal S; Tripathi M; Damle NA; Sahoo RK; Seth A; Bal C
Nucl Med Commun; 2017 Jan; 38(1):91-98. PubMed ID: 27782913
[TBL] [Abstract][Full Text] [Related]
20. Prostate-specific membrane antigen PET imaging and immunohistochemistry in adenoid cystic carcinoma-a preliminary analysis.
Klein Nulent TJW; van Es RJJ; Krijger GC; de Bree R; Willems SM; de Keizer B
Eur J Nucl Med Mol Imaging; 2017 Sep; 44(10):1614-1621. PubMed ID: 28593386
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
